US court upholds FDA's grant of five-year NCE exclusivity for Shire's Vyvanse
This article was originally published in Scrip
Executive Summary
A US district court judge has upheld an FDA decision to grant five years of market exclusivity to Shire's attention deficit/hyperactivity disorder (ADHD) drug, Vyvanse (lisdexamfetamine dimesilate), following a challenge by generics maker Actavis.